Pharmacy reverse distributors play a key role in making pharmaceutical returns more efficient, helping with processing, financial settlements and delivering helpful data. They're in a unique spot to support efforts to prevent diversion, speed up inventory returns, and even contribute to sustainability goals. Kyle Hoelting, director of pharmacy supply assurance and stewardship at Vizient, along with Paige Ivey, senior national accounts director, and Houston Blankinship, senior director of customer experience for healthcare product operations at Inmar Intelligence join host Carolyn Liptak, pharmacy executive director in Vizient Center for Pharmacy Practice Excellence and host for today's conversation.

Guest speakers:

Kyle Holting, Pharm.D, BCPS Senior Clinical Manager of Drug Information Vizient Center for Pharmacy Practice Excellence

Paige Ivey Senior National Accounts Director Inmar Intelligence

Houston Blankenship Senior Director of Customer Experience for Healthcare Product Operations Inmar Intelligence

Host: Carolyn Liptak, MBA, RPh Pharmacy Executive Director Vizient Verified Rx Host

Show Notes:

[01:05-03:33] Background for Kyle, Paige, Houston [03:34-05:10] How the pharmaceutical supply chain works and how everything is interconnected [05:10-09:32] How reverse distribution specifically supports pharmacy operations [09:33-11:16] How data that comes from reverse distribution can offer some great insights for pharmacy leaders [11:58-13:57] How data that comes from reverse distribution can give insight to drug shortages [13:58-16:42] Inmar's role with insight into drug shortages [16:43-21:05] Go-to resources for those wanting to explore more on stewardship and protective purchases

Links | Resources:

Drug shortage stewardship: A novel solution for an old problem

Vizient Essential Medications List

Vizient Key performance indicators for the management of drug shortages

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed

Recently, there has been a lot of interest generated by a new FDA approval. Suzetrigine (Journavx) was recently approved by the US Food and Drug Administration for the management of pain. Although there is a lot of excitement about having a new tool in the toolbox, there are certain limitations that are important to consider. In this episode of Verified Rx, Dave Peterson, pharmacist and drug information specialist for the University of Utah Health joins us to discuss this exciting new non opioid medication.

Guest speakers:

Dave Peterson, PharmD, BCPS

Drug Information Specialist

University of Utah Drug Information Service

Host:

Kerry Schwarz, PharmD, MPH

Senior Clinical Manager, Evidence-Based Medicine and Outcomes

Center for Pharmacy Practice Excellence (CPPE)

VerifiedRx Host

Show Notes:

[00:54-02:24] Information about Suzetrigine

[02:25-04:06] What distinguishes suzetrigine from other non-opioid analgesics

[04:07-05:09] What suzetrigine is indicated for

[05:10-06:14] How suzetrigine is being studied

[06:15-08:40] Surgical models and the endpoints that we commonly see in these studies

[08:41-10:25] Making sense of discordant study results

[10:26-12:02] Moving beyond the evidence to real world utilization of suzetrigine

[12:03-14:03] How cost factors into real-world utilization

[14:04-16:21] What Dave is keeping his eye on in terms of clinical concerns

[16:22-17:28] What Dave is excited about with the advent of suzetrigine

Links | Resources:

No pain, much gain?

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed

Traditional drug spending in the U.S. has surpassed specialty drug spending, and the primary force behind this trend is GLP-1 receptor agonists. These incretin-based therapies are transforming both the clinical and economic landscapes, from diabetes to obesity.

In this episode of the Center for Pharmacy Practice Excellence’s VerifiedRx podcast, host Tori Richie, Senior Consulting Director of Intelligence at Sg2 is joined by Vizient colleagues Stacy Lauderdale, AVP of Evidence-Based Medicine, Heather Pace, Senior Clinical Manager of Ambulatory Care, and Emily Fitt, Intelligence Consultant at Sg2. They delve into a comprehensive discussion on GLP-1s, covering topics from telehealth services and patient management strategies to the unique attributes that set these therapies apart.

Grab your coffee and get comfortable. This isn’t just a conversation; it’s a front-row seat to how GLP-1s are reshaping the future of obesity management.

Guest speakers:

Stacy Lauderdale, Pharm.D, BCPS

Associate Vice President

Vizient Center for Pharmacy Practice Excellence

VerifiedRx Host

Heather Pace, Pharm.D

Sr. Clinical Manager of Ambulatory Care,

Vizient Center for Pharmacy Practice Excellence

Emily Fitt, MHA, MPH

Consultant

Sg2

Host:

Tori Richie

Senior Consulting Director, Intelligence

Sg2

Sg2 Perspectives Host

Show Notes:

[02:24-04:50] How GLP-1 medications differ from traditional treatments and shift from use in diabetes to obesity management

[04:51-05:54] The most common side effects of GLP-1 therapies and how clinicians can effectively manage patients

[05:55-08:49] Treatment teams for obesity management and the role of the pharmacist in the management of GLP-1 medications

[08:50-10:51] Challenges providers face integrating GLP-1 medications into practice

[10:16-13:20] Quality or outcome concerns with individuals who receive GLP-1 medications from telehealth providers

[13:21-15:01] Trends shaping this landscape

[15:02-21:14] Best practices that providers should deploy

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed